登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心青岛大学附属医院Affiliated Hospital of Qingdao University青岛医院页面
- 研究中心上海市第六人民医院Shanghai Sixth People's Hospital上海医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07538973,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 65 岁;性别:不限
登记记录的入选字段
Hepatic impairment is caused by a previous primary liver disease (diagnosed at least 2 weeks prior to screening; excluding oncology patients) and is classified as Child-Pugh Class A or B;
入选标准第 10 条
No medication for liver disease within 4 weeks prior to screening, or on a stable medication regimen for existing underlying conditions.
入选标准第 12 条
Has a history of drug abuse within 3 months prior to screening, or tested positive for urine drug screening;
排除标准第 11 条
Creatinine clearance (CLcr) < 60 mL/min (calculated by the Cockcroft-Gault formula);
排除标准第 15 条
Tested positive for HIV or syphilis screening;
排除标准第 4 条
Used any CYP3A4 inhibitors (e.g., macrolide antibiotics such as clarithromycin, triazole antifungals such as itraconazole, and HIV protease inhibitors such as lopinavir) or CYP3A4 inducers (e.g., rifampicin, carbamazepine, and phenytoin) within 4 weeks prior to screening;
排除标准第 7 条
Suffered from drug- or virus-induced acute hepatitis within 2 months prior to screening;
排除标准第 21 条
Subjects and their partners agree to voluntarily adopt effective contraceptive measures from screening until 6 months after the last dose;
入选标准第 4 条
Female subjects who are lactating or test positive for pregnancy during screening or the trial period;
排除标准第 16 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;日常活动能力;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07538973,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Provide signed informed consent prior to trial participation and have a full understanding of the trial content, procedures, and potential adverse reactions; Be male or female subjects aged 18 to 65 years (inclusive); Weigh at least 50 kg for males and at least 45 kg for females. Body Mass Index (BMI = weight (kg) / height² (m²)) within the range of 18 to 30 kg/m² (inclusive of boundary values); Subjects and their partners agree to voluntarily adopt effective contraceptive measures from screening until 6 months after the last dose; Subjects are able to communicate well with the investigators and can complete the study according to the study protocol. Negative test results for Hepatitis B surface antigen and Hepatitis C antibody; Normal liver function test results or abnormal results without clinical significance; Matched with the hepatic impairment group in terms of male-to-female ratio (±1 subject per gender), mean age (±10 years), and mean body weight (±10 kg). Have a history of or be diagnosed at screening with primary liver disease, including but not limited to: Hepatitis B, Hepatitis C, non-alcoholic fatty liver disease, alcoholic liver disease, etc.; Hepatic impairment is caused by a previous primary liver disease (diagnosed at least 2 weeks prior to screening; excluding oncology patients) and is classified as Child-Pugh Class A or B; Liver function is stable within 2 weeks prior to taking the study drug, as determined by the investigator; No medication for liver disease within 4 weeks prior to screening, or on a stable medication regimen for existing underlying conditions.排除标准:Exclusion Criteria:
Suffering from primary diseases of major organs, including but not limited to gastrointestinal, respiratory, renal, neurological, hematological, endocrine, oncological, immune, psychiatric, or cardiovascular diseases, as determined by the Investigator to be unsuitable for participation in this trial (except for hepatic impairment patients regarding their primary liver disease and complications of hepatic impairment); Physical examination, vital signs, or clinical laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function) show abnormalities of clinical significance, as determined by the Investigator to be unsuitable for participation in this trial (except for hepatic impairment patients regarding their primary liver disease and complications of hepatic impairment); Participated in any drug clinical trial and used any investigational drug within 3 months prior to screening; Tested positive for HIV or syphilis screening; Subjects with conditions that may affect the absorption, distribution, metabolism, or excretion of the study drug (e.g., inability to swallow) or who have undergone gastrointestinal resection that may affect drug absorption, distribution, metabolism, or excretion; Electrocardiogram (ECG) abnormalities of clinical significance (e.g., tachycardia/bradycardia requiring medication, second- or third-degree atrioventricular block, or other abnormalities deemed clinically significant and unsuitable for participation by the Investigator); Used any CYP3A4 inhibitors (e.g., macrolide antibiotics such as clarithromycin, triazole antifungals such as itraconazole, and HIV protease inhibitors such as lopinavir) or CYP3A4 inducers (e.g., rifampicin, carbamazepine, and phenytoin) within 4 weeks prior to screening; Used any prescription drugs, over-the-counter medications, herbal medicines, or dietary supplements (e.g., vitamins, calcium supplements) within 2 weeks prior to screening, except for medications used by hepatic impairment patients to treat hepatic impairment and its complications; Known allergy to any component of TQ-B3101 capsules, or having an allergic constitution (including a history of drug allergy, prone to rashes, eczema, urticaria, asthma, etc.); Smoked an average of more than 5 cigarettes per day within 3 months prior to screening; Has a history of drug abuse within 3 months prior to screening, or tested positive for urine drug screening; Alcoholic liver disease patients have a history of alcoholism within 12 months prior to screening; other subjects have a history of alcoholism within 3 months prior to screening (average daily alcohol consumption > 2 units [1 unit = 360 mL beer or 45 mL 40% spirits or 150 mL wine]); Donated blood or plasma, lost ≥ 200 mL of blood, or undergone plasmapheresis within 4 weeks prior to screening; Consumed any food or beverage containing alcohol (or tested positive for alcohol breath test 1 day before dosing; alcoholic liver disease subjects consumed any alcohol-containing substances 2 weeks before dosing), grapefruit juice/pomelo juice, coffee, tea, cola, or chocolate within 1 week before dosing; Creatinine clearance (CLcr) < 60 mL/min (calculated by the Cockcroft-Gault formula); Female subjects who are lactating or test positive for pregnancy during screening or the trial period; Deemed by the Investigator to have any factors making them unsuitable for participation in this trial. History of liver transplantation; Experienced hepatic encephalopathy within 30 days prior to screening; Used any medication that may cause acute hepatotoxicity (e.g., halothane and methotrexate) within 3 months prior to screening; Suffered from drug- or virus-induced acute hepatitis within 2 months prior to screening; Experienced a rapid deterioration or Alanine Aminotransferase/Aspartate Aminotransferase (ALT/AST) elevation > 3 times the upper limit of normal within 2 weeks prior to dosing, as judged by the Investigator; Experienced worsening of hepatic encephalopathy within 30 days prior to dosing; Suffering from diseases affecting bile excretion, such as biliary cirrhosis, hepatic/biliary obstruction, or cholestatic liver disease; Patients with liver failure or complications deemed unsuitable by the Investigator, such as hepatic encephalopathy, hepatocellular carcinoma, esophageal-gastric variceal bleeding within 3 months, severe portal hypertension, or history of portosystemic shunt surgery; As judged by the Investigator, having concomitant medications that may potentially affect the evaluation of the pharmacokinetic characteristics of TQ-B3101 and its metabolites.
引自 ClinicalTrials.gov, NCT07538973, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07538973,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。